ID #648 Cerebrospinal fluid liquid biopsy: results following implementation into clinical practice for patients with pediatric central nervous system tumors
Katrina O’Halloran, Venkata Yellapantula, Tom Davidson, Nathan Robison, Benita Tamrazi, Jennifer Cotter, Jianling Ji, Mark Krieger, Jaclyn Biegel, Ashley MargolAbstract
Liquid biopsy (LB) is emerging in the care of pediatric central nervous system (CNS) tumors. Low-pass whole genome sequencing of cerebrospinal fluid (CSF) was validated as a clinical test (LBSeq4Kids) at our institution in 2022.
We report 123 CSF LBs from 48 patients (ages 7 months to 20 years) with CNS tumors at timepoints ranging from diagnosis through therapy to radiographic recurrence. Histologic diagnoses included medulloblastoma (n = 24), other embryonal tumor (n = 8), glioma (n = 9), others (n = 7). Collection utilized lumbar puncture (n = 73), Ommaya (n = 30), ventricular shunt (n = 10), ventriculostomy (n = 4), and other (n = 6). Twenty-four patients (50%) underwent serial sampling (mean: 4.2; range 2–10+ samples), enabling longitudinal molecular monitoring.
Circulating tumor DNA (ctDNA) was detected in 72/123 samples (59%), variable by timepoint: 14/22 (64%) at diagnosis, 8/18 (44%) at end-of-therapy (EOT), and 9/13 (69%) at radiographic recurrence. Compared to primary tumor sequencing, 31/48 (65%) LB results were different from primary tumors, with 17/48 (35%) detecting additional variants. In cases with serial sampling 35/63 (56%) of LBs demonstrated clonal evolution as evidenced by accrual of additional alterations.
In patients with positive CSF cytology, 13/15 (87%) had detectable ctDNA and in patients with negative cytology 54/98 (55%) had positive ctDNA. In patients with radiographic disease at the time of LB, 44/60 (73%) had detectable ctDNA and in patients without radiographic disease, 25/56 (45%) had ctDNA present.
Outcomes for 7 patients with positive ctDNA at EOT varied: 2 has disease recurrence and died of disease, 3 received continuation therapy without recurrence, and 2 remain recurrence-free off therapy (8 and 14 months off therapy).
LBSeq4Kids is feasible across various collection methods, demonstrates higher sensitivity than cytology, and provides insights into tumor evolution and sub-radiographic disease.